One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication

Gisbert, Javier P.; Carpio, Daniel; Marcos, Santiago; Gisbert, José Luis; Grávalos, R G; Jm, Pajares García

doi:10.1097/00042737-200012050-00003

Cited by 19 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nineteen of the trials were conducted in Europe [15][16][17][18]20,[23][24][25][27][28][29][30]37,40,[42][43][44][45]47] , eight in the Far East [21,22,32,35,36,38,46,48] , four in the USA [31,33,34,41] , one in the Middle East [26] , one in South America [19] , one in Australia [7] , and one was a multi-national study [39] . Eleven of the studies were multicentre RCTs [15,21,25,29,31,32,34,39,41,44,45] .…”

Section: Trial Characteristicsmentioning

confidence: 99%

“…Eleven of the studies were multicentre RCTs [15,21,25,29,31,32,34,39,41,44,45] . Duration of bismuth therapy ranged from 7 to 56 d, with a total daily dose of between 400 mg and 2100 mg. Nineteen studies used ranitidine bismuth citrate [15,17,20,22,24,[28][29][30][31][32]34,36,[39][40][41]43,45,46,48] , ten studies colloidal bismuth subcitrate [7,16,18,21,26,27,37,38,42,44] , two studies tripotassium dictrato bismuthate [23,35] , two studies bismuth subsalicylate [25,33] , one study bismuth subnitrate [19] , and one study both bismuth subnitrate and www.wjgnet.com…”

Section: Trial Characteristicsmentioning

confidence: 99%

“…Ten of the studies reported the method of generation of the randomization schedule [15,18,20,26,30,32,37,39,47,48] , but only four the method of concealment of allocation [27,32,47,48] . Four of the studies recorded adverse events using a questionnaire [20,24,28,40] , but only two of these stated that the questionnaire was validated [24,28] .…”

Section: Trial Qualitymentioning

confidence: 99%

“…Headache: Fourteen trials reported the total number of individuals experiencing headache with bismuth or bismuth-containing regimens versus comparison regimen [17,18,20,[24][25][26]30,31,34,[39][40][41]46,47] . Five of these studies utilized more than one regimen [20,31,34,41,47] , allowing 19 comparisons to be made.…”

Section: Dizzinessmentioning

confidence: 99%

“…Withdrawal of therapy due to adverse events with bismuth or bismuth-containing regimen versus comparison regimen Twenty-eight trials reported the total number of individuals who terminated therapy due to experiencing adverse events with bismuth or bismuth-containing regimens versus comparison regimen [16][17][18]20,[22][23][24][25][26][27][28][29][30][31][32][34][35][36][37][39][40][41][42][43][45][46][47][48] . Six of these studies utilized more than one regimen [20,31,34,35,41,47] , allowing 34 comparisons to be made.…”

Section: Nausea And/or Vomitingmentioning

confidence: 99%

See 4 more Smart Citations

Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis

Ford

Malfertheiner²,

Giguere³

et al. 2008

WJG

110

View full text Add to dashboard Cite

INTRODUCTIONBismuth salts have been used for centuries in medicine. From a gastroenterology perspective these drugs have been used to treat peptic ulcer disease, dyspepsia, parasitic infections, microscopic colitis, and infectious diarrhoea [1] . The discovery of Helicobacter pylori (H pylori) in 1983 by Warren and Marshall revolutionised the management of peptic ulcer disease [2] , and led to a renewed interest in bismuth compounds, largely because bismuth was found to inhibit the growth of H pylori and was effective in eradicating the organism (when combined with antibiotics or in combination with antibiotics and acid suppression therapy [3,4] ). The first randomised controlled trial (RCT) of bismuth in H pylori-positive individuals suggested that bismuth was superior to erythromycin monotherapy in eradicating the infection [5] . A further RCT of 6 wk of colloidal bismuth subcitrate versus cimetidine, in H pylori-positive duodenal ulcer patients, demonstrated that bismuth successfully eradicated the bacterium in up to 50% of patients [6] . Subsequently, an RCT of both colloidal bismuth subcitrate and cimetidine, alone or in combination with tinidazole, confirmed that colloidal bismuth subcitrate and tinidazole cleared the infection in almost 75% of patients [7] . With the addition of a second antibiotic, tetracycline or amoxicillin, eradication rates in later RCTs exceeded 80% [8][9][10] . However, there were some problems associated with bismuth-based triple therapy, which included the number of tablets patients were required to take, the duration of therapy, and side effects such as altered taste, nausea, and diarrhoea. Abstract AIM: To assess the safety of bismuth used in Helicobacter pylori (H pylori ) eradication therapy regimens. METHODS:We conducted a systematic review and meta-analysis. MEDLINE and EMBASE were searched (up to October 2007) to identify randomised controlled trials comparing bismuth with placebo or no treatment, or bismuth salts in combination with antibiotics as part of eradication therapy with the same dose and duration of antibiotics alone or, in combination, with acid suppression. Total numbers of adverse events were recorded. Data were pooled and expressed as relative risks with 95% confidence intervals (CI). RESULTS: We identified 35 randomised controlled trials containing 4763 patients. There were no serious adverse events occurring with bismuth therapy. There was no statistically significant difference detected in total adverse events with bismuth [relative risk (RR) = 1.01; 95% CI: 0.87-1.16], specific individual adverse events, with the exception of dark stools (RR = 5.06; 95% CI: 1.59-16.12), or adverse events leading to withdrawal of therapy (RR = 0.86; 95% CI: 0.54-1.37).CONCLUSION: Bismuth for the treatment of H pylori is safe and well-tolerated. The only adverse event occurring significantly more commonly was dark stools.

show abstract

Section: Trial Characteristicsmentioning

confidence: 99%

Section: Trial Characteristicsmentioning

confidence: 99%

Section: Trial Qualitymentioning

confidence: 99%

Section: Dizzinessmentioning

confidence: 99%

Section: Nausea And/or Vomitingmentioning

confidence: 99%

See 3 more Smart Citations

Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis

Ford

Malfertheiner²,

Giguere³

et al. 2008

WJG

110

View full text Add to dashboard Cite

show abstract

The authors reply:

Kadayıfçı¹,

Uygun²

2000

Clinical Therapeutics

View full text Add to dashboard Cite

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate‐ or proton pump inhibitor‐based triple therapies

Oijen

Verbeek

Jansen

et al. 2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Triple therapy, combining a proton pump inhibitor with clarithromycin (C) and either amoxycillin (A) or a nitro‐imidazole (I) is the standard in Helicobacter pylori eradication therapy. Recently, triple therapies based on ranitidine bismuth citrate (RBC) have emerged as an alternative. This review examines the current literature for studies directly comparing proton pump inhibitor‐ with RBC‐based triple therapies. Seventeen studies were identified, of which three have been published as a full paper. Eradication rates in an intention‐to‐treat analysis ranged from 51 to 98%. No large difference in cure rates between the different regimens was demonstrated, although the RBC‐I‐C combination was somewhat superior. No definite conclusions could be made about the impact of metronidazole or clarithromycin resistance since only three studies performed a formal resistance analysis. No serious side‐effects were reported, and dropout rates were equal for the two regimens. Both RBC‐ and proton pump inhibitor‐based triple therapies are highly effective. If one prefers a imidazole/clarithromycin combination the evidence presented here suggests that RBC should be used instead of a proton pump inhibitor. Larger studies comparing both forms of triple therapy, using proper resistance analysis, are needed before final conclusions can be reached regarding efficacy in the setting of bacterial resistance.

show abstract

One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication

Cited by 19 publications

References 0 publications

Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis

Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis

The authors reply:

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate‐ or proton pump inhibitor‐based triple therapies

Contact Info

Product

Resources

About